CSL Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares CSL Limited with three other
pharmaceutical manufacturers in Australasia:
sales of 79.09 million Australian Dollars [US$53.44 million]
AFT Pharmaceuticals Ltd
of New Zealand
(85.13 million New Zealand Dollars [US$53.57 million]
of which 59%
was Australia), and
Mayne Pharma Group Limited
(526.22 million Australian Dollars [US$355.56 million]
of which 61%
was Generic Products).
CSL Limited reported sales of A$11.95 billion (US$8.07 billion)
June of 2019.
increase of 16.7%
versus 2018, when the company's sales were A$10.23 billion.
Sales at CSL Limited have increased during each of the previous five years
(and since 2014, sales have increased a total of 98%).
Sales of Seqirus saw an increase
21.0% in 2019, from
A$1.18 billion to A$1.42 billion.